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Baicalin is a ﬂavonoid compound puriﬁed from the medicinal plant Scutellaria baicalensis Georgi and has been reported to
stimulate surfactant protein (SP)-A gene expression in human lung epithelial cell lines (H441). The aims of this study were
to determine whether maternal baicalin treatment could increase lung surfactant production and induce lung maturation
in fetal rats. This study was performed with timed pregnant Sprague-Dawley rats. One-day baicalin group mothers were
injected intraperitoneally with baicalin (5mg/kg/day) on Day 18 of gestation. Two-day baicalin group mothers were injected
intraperitoneally with baicalin (5mg/kg/day) on Days 17 and 18 of gestation. Control group mothers were injected with vehicle
alone on Day 18 of gestation. On Day 19 of gestation, fetuses were delivered by cesarean section. Maternal treatment with
2-day baicalin signiﬁcantly increased saturated phospholipid when compared with control group and total phospholipid in
fetal lung tissue when compared with control and 1-day baicalin groups. Antenatal treatment with 2-day baicalin signiﬁcantly
increased maternal growth hormone when compared with control group. Fetal lung SP-A mRNA expression and maternal serum
corticosterone levels were comparable among the three experimental groups. Maternal baicalin treatment increases pulmonary
surfactant phospholipids of fetal rat lungs and the improvement was associated with increased maternal serum growth hormone.
These results suggest that antenatal baicalin treatment might accelerate fetal rat lung maturation.
1.Introduction
Respiratory distress syndrome (RDS) is a major cause of
morbidity and mortality in preterm neonates. Maternal
glucocorticoid treatments given to women at high risk of
preterm delivery have been used extensively to decrease the
incidence and severity of RDS [1]. It was suggested that the
beneﬁcial eﬀect of glucocorticoid did not occur if there was
an interval of over 7 days between treatment and delivery
[2]. These ﬁndings persuaded obstetricians to repeat the
course of glucocorticoid after 7 days in pregnant women
at risk of preterm delivery who had not yet given birth.
However, there is considerable evidence from laboratory and
clinicalstudiesthatrepeatedantenatalsteroidadministration
is associated with decreased birth body weight, length and
head circumference and no additional beneﬁts in preterm-
birth outcomes [3, 4]. These studies indicate that maternal
glucocorticoid could not completely prevent the incidence of
RDS and have untoward neurological side eﬀects after mul-
tiple doses and that there are other potent lung maturation
factors that remain to be identiﬁed.
The extract from the root of Scutellaria baicalen-
sis Georgi (Scutellaria Radix) is the main component
in Chinese medicine prescribed for miscarriage, threat-
ened abortion, and neonatal hyperbilirubinemia. It is
composed of four major ﬂavenoids, that is, baicalin,
baicalein, wogonin and wogonoside. Baicalin (Figure 1),
5,6,7-trihydroxyﬂavone-7-β-D-glucuronide, has antibacte-
rial, antiviral, anti-inﬂammatory, anti-oxidative and anti-
cancer activities [5–8]. It has been used as an anti-
inﬂammatory and protective agents in the treatment of
experimental pancreatitis and liver injury [9, 10]. We
found that baicalin stimulates surfactant protein (SP)-
A gene expression through induction of cytochrome c
oxidase in human lung epithelial cell lines (H441) [11].
We hypothesized that maternal baicalin treatment might2 Evidence-Based Complementary and Alternative Medicine
increase fetal lung surfactant production in vivo in preterm
rats and quantiﬁed the eﬀects by biochemical and molecular
analyses.
2. Methods
2.1. Animals and Experimental Procedures. The Animal Care
and Use Committee at Taipei Medical University approved
this study. This study was performed with timed pregnant
Sprague-Dawley rats (vaginal smear positive, Day 0; term,
Day 22). One-day baicalin group mothers (n = 2) were
injected intraperitoneally (i.p.) with baicalin (5mg/kg/day,
Wako Pure Chemical Industries, Japan) on Day 18 of
gestation. Two-day baicalin group mothers (n = 3) were
injected i.p. with baicalin (5mg/kg/day) on Days 17 and 18
of gestation. Baicalin was dissolved in dimethyl sulfoxide
(DMSO) at a concentration of 5mg/ml. The dose of baicalin
was based on the work of P.-L. Tsai and T.-H. Tsai [12].
Control group mothers (n = 3) were similarly injected with
DMSO alone on Day 18 of gestation. On Day 19 of gestation,
all dams were anesthetized with pentobarbital (50mg/kg,
i.p., Abbott Laboratories, North Chicago, IL, USA), and
cesarean section was used to deliver the fetuses. At delivery,
the fetuses were weighed and killed by an i.p. injection of
pentobarbital (100mg/kg). The organs of interest were then
dissectedfreeandweighedtothenearest0.1mg.Resultswere
expressed as organ weight and the ratio (%) of organ/body
weight.Afterdeliveryofthefetuses,abloodsamplewastaken
from the pregnant mother before she was sacriﬁced. Plasma
was immediately separated from blood cells by centrifuga-
tion and kept at –20◦C for hormone measurements.
2.2. Biochemical Analysis. Lungs were homogenized and
aliquots were extracted with chloroform-methanol [13].
Lipid extracts from aliquots of the lung homogenates were
treated with osmium tetroxide, and saturated phospho-
lipid was recovered by alumina column chromatography
and quantiﬁed using a phosphorus assay [14, 15]. Values
were expressed as ¯mol/g protein. Aliquots of the lung
homogenatefromeachanimalwereusedtomeasurethetotal
protein content by Bio-Rad protein assay kit using bovine
serum albumin as a standard.
Maternal serum growth hormone concentrations were
measured using a commercially available radioimmunoassay
kit (Diagnostic Systems Laboratories, Webster, TX, USA).
Maternal serum corticosterone levels were measured using
an enzyme immunoassay kit (BIOCODE, Li` ege, Belgium).
2.3. Molecular Analysis. Gene expression of SP-A was
measured with reverse transcriptase-polymerase chain
reaction (RT-PCR). Total RNA was isolated from lung
using the guanidine isothiocyanate based TRIzol solution
(Invitrogen Life Technologies, Paisley, UK) according
to the manufacturer’s speciﬁcations and quantiﬁed by
measurement of absorbance at 260nm. Total RNA (2¯g) was
converted to ﬁrst strand cDNA with oligo(dT) primer and
reverse transcriptase. The primer sequences used in PCR
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Figure 1: Chemical structure of baicalin.
Table 1: Maternal treatment eﬀects on fetal body weight and
lung/body weight ratio.
Treatment n Body weight
(g)
Lung weight
(g)
Lung/body
weight (%)
Control 27 2.48 ± 0.07 0.098 ± 0.004 3.90 ± 0.09
Baicalin
(1 day) 21 2.62 ± 0.05 0.094 ± 0.002 3.63 ± 0.08
Baicalin
(2 days) 22 2.46 ± 0.05 0.092 ± 0.002 3.80 ± 0.07
Values are mean ± SEM. n is the number of fetuses tested.
and 5 -AGGCTTTGTCCCCACAG-3  with an expected size
of 558 base pairs (accession no. M33201). β-Actin (BD
Biosciences Clontech, Palo Alto, CA, USA) was used as
an internal control. The PCR reactions were carried out
using the following conditions: 94◦Cf o r1m i nf o l l o w e db y
60◦Cf o r1m i na n d7 2 ◦C for 1min. The primer annealing
temperature was 60◦C with 29 cycles for SP-A and 33 cycles
for β-actin. SP-A mRNA expressions were determined by
running the samples at the optimal cycle number, which was
selected in the region of linearity between cycle number and
PCRproductintensity.Productswerevisualizedonethidium
bromide-stained gels and quantiﬁed using the BioRad Gel
Documentation System (BioRad Laboratories, Hercules, CA,
USA).
2.4. Statistical Analysis. Results are presented as the mean
± SEM. Statistically signiﬁcant diﬀerences were analyzed
by ANOVA followed by Bonferroni post hoc analysis.
Diﬀerences were considered signiﬁcant at P<. 05.
3. Results
There were 27 fetuses from three rats in the control group,
21 fetuses from two rats in the 1-day baicalin group and 22
fetuses from three rats in the 2-day baicalin group. There
was no signiﬁcant diﬀerence in litter size among the three
experimental groups.
3.1.MaternalBaicalinTreatmentEﬀectsonFetalBodyWeight,
Organ Weight and Organ/Body Weight Ratio (%). Eﬀects
of maternal baicalin treatment on fetal body weight and
the organ/body weight ratio (%) are presented in Tables 1
and 2. The body weight, lung, brain and kidney weights,
and lung/body weight, brain/body weight and kidney/body
weightratioswerecomparableamongthethreeexperimentalEvidence-Based Complementary and Alternative Medicine 3
Table 2: Maternal treatment eﬀects on organ weight and organ/body weight ratio.
Treatment n Brain weight
(g)
Brain/body
weight (%)
Kidney weight
(g)
Kidney/body
weight (%)
Liver weight
(g)
Liver/body
weight (%)
Control 27 0.109 ± 0.003 4.47 ± 0.12 0.020 ± 0.001 0.81 ± 0.02 0.22 ± 0.01 8.67 ± 0.21
Baicalin (1 day) 21 0.113 ± 0.002 4.37 ± 0.08 0.020 ± 0.000 0.79 ± 0.02 0.23 ± 0.00 8.97 ± 0.17
Baicalin (2 days) 22 0.113 ± 0.04 4.32 ± 0.15 0.021 ± 0.001 0.81 ± 0.02 0.25 ± 0.01∗ 9.54 ± 1.01∗∗
Values are mean ± SEM. n is the number of fetuses tested. ∗P<. 05, ∗∗P<. 01 compared with the control group.
Table 3: Maternal treatment eﬀects on saturated phosphatidyl-
choline and total phospholipids in fetal lung tissue of preterm rats.
Treatment n Saturated phospholipid
(μmol/g protein)
Total phospholipid
(μmol/g protein)
Control 9 31.02 ± 0.98 199.21 ± 9.57
Baicalin
(1 day) 6 36.09 ± 1.45 216.24 ± 4.67
Baicalin
(2 days) 13 39.35 ± 1.97# 636.01 ± 92.20∗∗
Values are mean ± SEM. n i st h en u m b e ro ff e t u s e st e s t e d .∗∗P<. 01
compared with the control and 1-day baicalin groups, #P<. 01 compared
with the control group.
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Figure 2: Maternal baicalin treatment eﬀects on SP-A mRNA
expressionoffetallungtissueinthecontrol(n = 23),1-daybaicalin
(n = 19)-and2-daybaicalin(n = 15)-treatedpretermrats.Dataare
expressed as the mean ± SEM.
groups. Two-day baicalin-treated fetuses had signiﬁcantly
higher liver weight and liver/body weight ratio than did the
control group.
3.2. Fetal Lung Phospholipid. Maternal treatment with
baicalinincreasedsaturatedphospholipid infetallungtissue,
and the value reached statistical signiﬁcance in the 2-day
baicalin-treated group when compared with control animals
(Table 3). Two-day baicalin-treated fetuses had signiﬁcantly
higher total phospholipid than did the control and 1-day
baicalin-treated groups.
3.3. Fetal Lung SP-A mRNA Expression. T h eS P - Am R N A
expression in fetal lung tissue was comparable among the
three experimental groups (Figure 2).
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Figure 3: (a) Growth hormone and (b) corticosterone serum levels
in the control (n = 3), 1-day baicalin (n = 2)- and 2-day baicalin
(n = 3)-treated dams. Data are expressed as the mean ± SEM. ∗P<
.05 compared with the control group.
3.4. Growth Hormone and Corticosterone Levels in Maternal
Serum at Delivery. Antenatal treatment with 2-day baicalin
signiﬁcantly increased maternal growth hormone when
compared with control group (Figure 3(a)). Corticosterone
concentrations in maternal serum were comparable among
the three experimental groups (Figure 3(b)).
4. Discussion
Neonatal respiratory failure is a serious clinical problem
associated with high morbidity, mortality and costs [16,
17]. The major risk factor is premature birth and its
associated RDS. The pathophysiology of RDS is an imma-
ture lung structure and a deﬁcit of pulmonary surfactant.
Glucocorticoids have been reported to enhance fetal lung
maturation and surfactant production [18]. However, there
is considerable evidence that glucocorticoids have an adverse4 Evidence-Based Complementary and Alternative Medicine
eﬀect on the growth and development of the immature brain
[3, 4]. Baicalin has been reported to stimulate SP-A gene
expression in vitro after 48h of incubation [11]. Therefore,
we investigated the eﬀects of antenatal baicalin treatment
48h before birth in preterm rats that have been shown to be
a suitable model for the study of acute neonatal lung disease
[19].
In this study, we found that antenatal baicalin treatment
did not inﬂuence fetal body, brain, lung and kidney weight
and 2-day baicalin treatment signiﬁcantly increased liver
weight and liver/body weight ratio as compared with that
of the control group. It appears that baicalin promotes
liver growth in this premature animal model. The increase
in liver weight in the oﬀspring of baicalin-treated dams
is of interest, as others have reported that baicalin could
prevent experimental hepatic ﬁbrosis [20], although, to
our knowledge, no increase in liver weight has been
recorded.
Pulmonary surfactant stabilizes the lung by producing
a surface-active monolayer that reduces the surface tension
at the air-liquid interface of the terminal airways. This
reduction in surface tension contributes to mechanical
stability by preventing alveolar and bronchiolar collapse
during expiration. Surfactant is composed of ∼90% lipids
and 10% proteins. The surface activity property is due pri-
marily to dipalmitoylphosphatidylcholine, which is ∼50% of
surfactant by weight. Therefore, we measured the saturated
phospholipid content in fetal lung tissue in this premature
animal model. Four lung-speciﬁc proteins (SP-A, SP-B, SP-
C and SP-D) have been found to be associated with the
surfactant [21]. Surfactant proteins are required both for
the transition between lamellar bodies and tubular myelin,
and for the spreading of tubular myelin components to
the surface ﬁlm. SP-A, the major pulmonary surfactant-
associated protein, is a developmentally and hormonally
regulated sialoglycoprotein of about 35000 mol wt. con-
stituting about 50% of the total surfactant protein [22].
In addition to its direct eﬀects on ﬁlm adsorption and
stability, SP-A seems to enhance the resistance of surfactant
to protein inhibition and stimulates phagocytosis of bacteria
and viruses by alveolar macrophages [23]. In this study,
we found that antenatal baicalin treatment increased total
phospholipidsandsaturatedphospholipidlevels,anddidnot
aﬀect SP-A mRNA expression in fetal lung tissue. This result
is in contrast to our previous report of increased SP-A gene
expression after incubation of H441 cells in the presence of
baicalin [11]. These diﬀerences may suggest that a higher
level of baicalin stimulation is required to enhance in vivo
surfactant protein gene expression or cell-cell and matrix-
cell interactions might be implicated in the modulation of
baicalin eﬀects in lung development.
In this study, we found that 2-day baicalin treatment
signiﬁcantly increased maternal growth hormone levels.
Growth hormone appears to have important eﬀects on
fetal metabolism and development. Lung is established
as a target site for pituitary growth hormone action as
pathophysiologicalstatesofpituitarygrowthhormoneexcess
and deﬁciency are associated with impaired pulmonary
function [24, 25]. Growth hormone may be involved in lung
Maternal baicalin treatment
Anterior pituitary
Adrenal gland
Growth hormone
Fetal lungs
Fetal lung surfactant phospholipids
Figure 4: A hypothetical scheme of maternal baicalin treatment
increases fetal rat lung surfactant phospholipids. Solid arrow
indicates stimulation and dashed arrow indicates no eﬀect.
development becauseitis presentinextra-pituitary tissuesof
rat embryos [26]. The growth hormone receptor gene is also
expressed in pulmonary tissues [27, 28]. Therefore, pituitary
growth hormone is possible to be an endocrine regulator
of lung growth. These results suggest that baicalin has
some hormonal eﬀects. However, maternal corticosterone
levels were comparable in the control and baicalin-treated
groups. This result indicates that baicalin has no inhibitory
eﬀect on hypothalamic-pituitary-adrenal axis and the lung
maturational eﬀects of baicalin occurred independently of
corticosterone [29].
In conclusion, maternal baicalin treatment at a dose of
5mg/kg/day on Days 17 and 18 of gestation increases fetal
rat lung surfactant phospholipids and the improvement was
associated with increased maternal serum growth hormone.
Figure 4 is a hypothetical scheme of maternal baicalin
treatment increases fetal rat lung surfactant phospholipids.
These results suggest that antenatal baicalin treatment might
accelerate fetal rat lung maturation.
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